Brolucizumab-Dbll
Brolucizumab-Dbll (Beovu) is an anti-VEGF antibody fragment used to treat certain neovascular eye conditions. It is administered as an intravitreal injection and works by inhibiting vascular endothelial growth factor A (VEGF-A) to reduce abnormal blood vessel growth and fluid leakage in the retina.
Brolucizumab-Dbll is an eye injection medication that treats wet AMD and diabetic macular edema by blocking VEGF-A to reduce abnormal blood vessel growth and fluid buildup in the retina.
Key facts at a glance
- RxNorm
- 2204916
- Generic
- Brolucizumab-Dbll
- Class
- pin-variant
- Brands
- Beovu
- Availability
- rx
- Lactation
- unknown
- Routes
- —
- Forms
- —
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Treats neovascular (wet) age-related macular degeneration (AMD), diabetic macular edema (DME), and macular edema secondary to retinal vein occlusion. It is prescribed when abnormal blood vessel growth and fluid leakage in the retina threaten vision.
As a humanized single-chain antibody fragment, brolucizumab-Dbll binds to and inhibits vascular endothelial growth factor A (VEGF-A), a protein that promotes abnormal blood vessel formation and increases vascular permeability. By blocking VEGF-A, it reduces neovascularization, decreases fluid leakage, and helps preserve or improve vision.
Administered via intravitreal injection by an eye care professional. Common side effects include eye redness, floaters, and mild eye discomfort. Serious risks include endophthalmitis, retinal detachment, and increased intraocular pressure. Regular follow-up injections are typically required for sustained benefit. Patients should report any signs of infection or vision changes immediately.
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy